Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus placebo after pleurectomy/decortication for malignant pleural mesothelioma
2020-003762-39Phase 3Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started May 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2020-003762-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003762-39.